Standardizing Genetic Diagnostics in Spain
Spain’s National Health System is moving toward a more structured approach to genetic testing by establishing a national catalog for molecular diagnostics. Known as the CGEN, this framework aims to ensure consistent access to pharmacogenomic evaluations across all autonomous communities. The initiative gained momentum following a June 2023 agreement and a subsequent ministerial order in June 2024 that formalized an Advisory Committee for the portfolio. This body includes experts from the Carlos III Health Institute and various scientific societies, tasked with expanding the catalog to cover more high-impact medical conditions.
The CGEN currently incorporates 12 pharmacogenetic markers covering 22 specific drugs. By testing for these markers, physicians aim to predict how a patient will metabolize a medication, thereby reducing the risk of adverse reactions and improving therapeutic outcomes. While the system provides a formal path for requesting these tests, practical application remains subject to regional variation. Some tests, such as DPYD screening before fluoropyrimidines or HLA-B57:01 before abacavir, are already established as mandatory prerequisites in drug labeling.
The Role of Preemptive Testing
Recent developments emphasize the value of preemptive genotyping, where genetic profiles are stored permanently in electronic health records for future reference. This strategy prevents the need for repeated testing and offers significant advantages for elderly patients managing polypharmacy. Research from the PREPARE study, a large European trial involving nearly 7,000 individuals, demonstrated that using a 12-gene pharmacogenetic panel can reduce clinically relevant adverse drug reactions by approximately 30 percent. This trial confirmed that multigene panels are safe and effective when used to guide treatment decisions across primary and specialized care settings.
Despite the clear clinical utility, the integration of these findings into primary care faces hurdles. Current practice in the National Health System remains largely reactive, where testing is often performed only after a patient experiences safety or efficacy issues with a specific medication. Statins provide a notable example of this gap. While international guidelines suggest preventive testing for markers like SLCO1B1, the current CGEN criteria limit this assessment to patients who have already suffered severe muscle toxicity from simvastatin. The disparity between international recommendations and local implementation highlights the ongoing challenges of scaling genomic medicine.
Future Implementation and Data Management
The expansion of the CGEN is an iterative process governed by the Advisory Committee. New drugs enter the catalog only after a rigorous review of scientific evidence and approval from the Commission on Benefits, Insurance, and Financing. For instance, mavacamten, used to treat hypertrophic cardiomyopathy, requires CYP2C19 phenotype knowledge for proper dosing. Similarly, Alzheimer’s treatments like lecanemab demand APOE status verification to avoid contraindications. Such requirements underscore the importance of maintaining an updated and accessible catalog.
Technological barriers still complicate the broader use of pharmacogenetic data. While some hospitals employ panels that analyze multiple genes simultaneously, most healthcare centers lack the infrastructure to interpret or store this surplus data effectively. Consequently, information collected for one specific clinical purpose often sits dormant rather than informing future prescriptions for other conditions. Addressing these technical gaps in electronic health records is now a primary objective. Until these systems are standardized, the full benefit of preemptive testing will remain out of reach for many patients in the Spanish healthcare system.